3 Pharma Excipients and Food Ingredients Maker, Pharmaceutical Company and Dairy Products Company Stocks With a Strong Future Roadmap: Sudeep Pharma, Ipca Laboratories and Dodla Dairy

Excipient, pharma and dairy stocks bring together companies with a visible plan for the years ahead. Sudeep Pharma, Ipca Laboratories and Dodla Dairy cover a pharma excipients and ingredients maker, a pharmaceutical company and a dairy products company.

This list covers three excipient, pharma and dairy stocks with complete current figures: Sudeep Pharma, Ipca Laboratories and Dodla Dairy. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Excipient, Pharma and Dairy Stocks?

Excipient, pharma and dairy stocks are listed companies that make pharmaceutical excipients and nutrition ingredients, produce formulations and active ingredients for domestic and export markets, and procure, process and sell milk and dairy products. Their earnings depend on medicine demand, ingredient orders and consumer dairy sales.

Excipient, Pharma and Dairy Stocks at a Glance

On valuation, Ipca Laboratories and Dodla Dairy trade at a P/E below the industry P/E, while Sudeep Pharma trades above it, which reflects the growth the market already expects. Readers comparing excipient, pharma and dairy stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Excipient, Pharma and Dairy Stocks Have a Strong Roadmap in India?

Excipient, pharma and dairy stocks have a strong roadmap in India because growing global demand for quality pharma ingredients, steady medicine consumption and rising packaged dairy use keep widening the market for these companies.

• Excipients. Every tablet and capsule needs quality inputs.
• Pharma. Medicines reach more domestic and export markets.
• Dairy. Households buy more milk and curd.

Why Sudeep Pharma Features Among These Excipient, Pharma and Dairy Stocks

Among the excipient, pharma and dairy stocks on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.

Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%.

In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.

Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

What to watch: Check capacity expansion progress and export revenue growth.

Why Ipca Laboratories Features Among These Excipient, Pharma and Dairy Stocks

Among the pharma ingredient, medicine and milk shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%.

Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Why Dodla Dairy Features Among These Excipient, Pharma and Dairy Stocks

Among the three companies on this list, Dodla Dairy, based in Hyderabad, procures milk from farmers and sells milk and value-added products such as curd, ghee and ice creams across South and East India, with operations in Africa.

The company has a return on equity of 15.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 6,064 crore. The stock trades at a P/E of 24.8, below the industry P/E of 33.9.

Revenue rose from Rs 2,257 crore in FY22 to Rs 4,186 crore in FY26, a compound annual growth rate of 16.7%. Net profit grew from Rs 133 crore in FY22 to Rs 267 crore in FY26, which works out to a compound annual growth rate of 19.1%. In the June 2026 quarter, revenue grew 18.3% year on year to Rs 1,212 crore.

Roadmap: The company is growing its value-added products, widening its geographic coverage and adding procurement strength. Value-added dairy brings better margins than plain milk, and a bigger farmer base secures supply.

What to watch: Track milk procurement prices and the growth in value-added products.

Sudeep Pharma vs Ipca Laboratories vs Dodla Dairy on Key Financials

The table below sets the three excipient, pharma and dairy stocks side by side on revenue, profit and margin, using reported figures.

Sudeep Pharma posts the highest return on equity in this group at 19.6%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and Sudeep Pharma shows the fastest revenue growth with a 17.6% compound annual rate. A useful habit with excipient, pharma and dairy stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Excipient, Pharma and Dairy Stocks

Every theme carries risks that deserve a check before any decision. For these excipient, pharma and dairy stocks, the main points are: Long-term pharma ingredient, medicine and milk shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Raw material costs. Ingredient and packaging prices can move margins.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter excipient, pharma and dairy stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Excipient, Pharma and Dairy Stocks

Excipient, pharma and dairy stocks suit investors who prefer to study business strength before price moves. Sudeep Pharma, Ipca Laboratories and Dodla Dairy each have a clear plan to grow. Based on the 5 November 2026 close, Sudeep Pharma trades at Rs 1,190.3, Ipca Laboratories at Rs 1,949.6 and Dodla Dairy at Rs 989.75. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these excipient, pharma and dairy stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track excipient, pharma and dairy stocks, set price alerts and get research-backed stock ideas.

What are excipient, pharma and dairy stocks?

Ans. Excipient, pharma and dairy stocks are listed companies that make pharmaceutical excipients and nutrition ingredients, produce formulations and active ingredients for domestic and export markets, and procure, process and sell milk and dairy products. Their earnings depend on medicine demand, ingredient orders and consumer dairy sales. This list looks at three of them, Sudeep Pharma, Ipca Laboratories and Dodla Dairy, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.

Which excipient, pharma and dairy stocks are covered in this list?

Ans. This list covers Sudeep Pharma, Ipca Laboratories and Dodla Dairy. Based on the 5 November 2026 close, Sudeep Pharma traded at Rs 1,190.3, Ipca Laboratories at Rs 1,949.6 and Dodla Dairy at Rs 989.75. Their return on equity ranges from 14.2% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 13.6% to 17.6%.

Why do excipient, pharma and dairy stocks have a strong future roadmap in India?

Ans. Excipient, pharma and dairy stocks have a strong roadmap in India because growing global demand for quality pharma ingredients, steady medicine consumption and rising packaged dairy use keep widening the market for these companies. The main drivers are as follows. Excipients. Every tablet and capsule needs quality inputs. Pharma. Medicines reach more domestic and export markets. Dairy. Households buy more milk and curd. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Sudeep Pharma performed financially?

Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

How has Dodla Dairy performed financially?

Ans. Revenue rose from Rs 2,257 crore in FY22 to Rs 4,186 crore in FY26, a compound annual growth rate of 16.7%. Net profit grew from Rs 133 crore in FY22 to Rs 267 crore in FY26, which works out to a compound annual growth rate of 19.1%. In the June 2026 quarter, revenue grew 18.3% year on year to Rs 1,212 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 6,064 crore. The stock trades at a P/E of 24.8, below the industry P/E of 33.9. Looking ahead, the company is growing its value-added products, widening its geographic coverage and adding procurement strength. Value-added dairy brings better margins than plain milk, and a bigger farmer base secures supply.

What risks should investors check before buying excipient, pharma and dairy stocks?

Ans. Investors should check a few risks before buying excipient, pharma and dairy stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material costs. Ingredient and packaging prices can move margins. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of excipient, pharma and dairy stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.